1 BTC
=
- USD
Aditxt, Inc. Common Stock
As of May 29, 2026 at 10:32 UTC
Chart
About Aditxt, Inc. Common Stock
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues. The company operates in one segment, which is focused on the discovery and development of biopharmaceutical products.
Market Statistics
Trading Metrics
How to Buy ADTX
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy ADTX
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articles
Women's health company Evofem Biosciences reported increased net sales of $5.0 million in Q3 2025, a 10% increase from the previous year. The company achieved $1.0 million in operating income, reduced operating expenses by 42%, and advanced strategies to lower manufacturing costs for its products PHEXX and SOLOSEC.
Evofem Biosciences plans to merge with Aditxt, with a stockholder meeting scheduled for September 26, 2025. The company believes it has sufficient voting support to approve the merger, which would position Evofem as a subsidiary of Aditxt focused on women's healthcare innovations.